[1]周 煜.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的影响[J].医学信息,2019,32(22):132-134.[doi:10.3969/j.issn.1006-1959.2019.22.044]
　ZHOU Yu.Effect of Entecavir Combined with Microecological Preparation on Liver Function and Prognosis in Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2019,32(22):132-134.[doi:10.3969/j.issn.1006-1959.2019.22.044]
点击复制

恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年22期
页码:
132-134
栏目:
药物与临床
出版日期:
2019-11-15

文章信息/Info

Title:
Effect of Entecavir Combined with Microecological Preparation on Liver Function and Prognosis in Patients with Hepatitis B Cirrhosis
文章编号:
1006-1959（2019）22-0132-03
作者:
周 煜
（江西省会昌县人民医院内三科，江西 会昌 342600）
Author(s):
ZHOU Yu
(Department of Internal Medicine,Subject Three,People's Hospital of Huichang County,Huichang 342600,Jiangxi,China)
关键词:
恩替卡韦; 微生态制剂; 乙肝肝硬化; 肝功能
Keywords:
Entecavir; Microecological preparation; Hepatitis B cirrhosis; Liver function
分类号:
R575.2
DOI:
10.3969/j.issn.1006-1959.2019.22.044
文献标志码:
A
摘要:
目的 分析恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的影响。方法 选取2018年5月~2019年5月在我院治疗的乙肝肝硬化患者156例，采用随机分为对照组和观察组，各78例。对照组采用恩替卡韦治疗，观察组在对照组治疗基础上联合微生态制剂治疗，比较两组临床治疗前后肝功能指标、临床症状评分、肝纤维化指标及血清HBV-DNA转阴率。结果治疗后两组ALT、ALT、TBIL均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组乏力、厌食、腹胀评分低于对照组，差异有统计学意义（P＜0.05）；两组肝纤维化指标（HA、PC-Ⅲ、Ⅳ-C）均较治疗前改善，且观察组改善优于对照组，差异有统计学意义（P＜0.05）；治疗后两组门静脉内径和脾脏厚度均较治疗前降低，且观察组低于对照组，差异有统计学意义（P＜0.05）。结论 恩替卡韦联合微生态制剂治疗乙肝肝硬化患者，可改善临床患者症状、肝功能，具有理想的治疗效果，为改善患者预后提供有利的条件。
Abstract:
Objective To analyze the effects of entecavir combined with microecological preparations on liver function and prognosis in patients with hepatitis B cirrhosis. Methods A total of 156 patients with hepatitis B cirrhosis who were treated in our hospital from May 2018 to May 2019 were randomly divided into control group and observation group, 78 cases each. The control group was treated with entecavir. The observation group was treated with microecological preparations on the basis of the control group. The liver function index, clinical symptom score, liver fibrosis index and serum HBV-DNA negative rate were compared before and after clinical treatment. Results After treatment, the levels of ALT, ALT and TBIL were lower than those before treatment, and the observation group was lower than the control group,the difference was statistically significant (P<0.05). The scores of fatigue, anorexia and abdominal distension in the observation group were lower than those in the control group,the difference was statistically significant (P<0.05). The liver fibrosis indexes (HA, PC-Ⅲ, Ⅳ-C) of the two groups were better than those before treatment, and the improvement of the observation group was better than that of the control group,the difference was statistically significant (P<0.05); after treatment, the portal vein diameter and spleen thickness of the two groups were lower than those before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). Conclusion Entecavir combined with microecological preparations for the treatment of patients with hepatitis B cirrhosis can improve the symptoms and liver function of clinical patients, and has an ideal therapeutic effect, which provides favorable conditions for improving the prognosis of patients.

参考文献/References:

[1]胡兴龙,王胜智,康志龙,等.乙型肝炎继发肝癌患者TACE术围术期使用恩替卡韦的临床观察[J].中国药房,2017,28(2):246-249. [2]杨景.恩替卡韦联合阿德福韦酯治疗乙型肝炎的疗效观察[J].中外医学研究,2014,12(19):140-142. [3]林小萍,侯卫平,陆军平,等.恩替卡韦联合微生态制剂对乙肝肝硬化患者肝功能及预后的临床研究[J].实用医学杂志,2016,32(6):993-995. [4]戴善梅,张亚丽,许伟,等.恩替卡韦联合复方鳖甲软肝片治疗乙型肝炎早期肝硬化疗效观察[J].肝脏,2014,19(12):958-959. [5]林厚雄.替诺福韦与恩替卡韦治疗HBeAg阳性初治慢性乙型肝炎患者的临床疗效[J].山东医药,2016,56(33):92-94. [6]冯因克,刘亚敏,陈启龙,等．慢性乙型肝炎后肝硬化中西医治疗研究进展[J].中国医药导报,2016,13(29):28-31．

相似文献/References:

[1]唐平阳.恩替卡韦抗病毒治疗失代偿期乙肝肝硬化患者的 临床疗效分析[J].医学信息,2018,31(10):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
　TANG Ping-yang.Analysis of Clinical Efficacy of Entecavir Antiviral Therapy in Decompensated Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(22):129.[doi:10.3969/j.issn.1006-1959.2018.10.042]
[2]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Journal of Medical Information,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[3]马 琳,田瑞民.乙型病毒性肝炎相关晚期肝病的抗病毒治疗效果观察[J].医学信息,2019,32(07):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
　MA Lin,TIAN Rui-min.Observation on the Effect of Antiviral Therapy For Advanced Hepatopathy Associated with Viral Hepatitis B[J].Journal of Medical Information,2019,32(22):120.[doi:10.3969/j.issn.1006-1959.2019.07.036]
[4]李嘉丽,温 静,周 甦,等.主动随访督导乙型肝炎肝硬化长期依从抗病毒的效果[J].医学信息,2019,32(10):178.[doi:10.3969/j.issn.1006-1959.2019.10.060]
　LI Jia-li,WEN Jing,ZHOU Su,et al.Active Follow-up to Monitor the Long-term Compliance with Antiviral Effects of Hepatitis B Cirrhosis[J].Journal of Medical Information,2019,32(22):178.[doi:10.3969/j.issn.1006-1959.2019.10.060]
[5]陈新华.拉米夫定联合恩替卡韦治疗乙型肝炎相关肝硬化的 长期疗效与安全性分析[J].医学信息,2019,32(18):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
　CHEN Xin-hua.Long-term Efficacy and Safety of Lamivudine Combined with Entecavir in the Treatment of Hepatitis B-related Cirrhosis[J].Journal of Medical Information,2019,32(22):151.[doi:10.3969/j.issn.1006-1959.2019.18.052]
[6]张 娜.不同种类核苷类似物治疗慢性乙型肝炎患者的疗效及对HBsAg水平的影响[J].医学信息,2021,34(09):96.[doi:10.3969/j.issn.1006-1959.2021.09.025]
　ZHANG Na.Efficacy of Different Kinds of Nucleoside Analogues in the Treatment of Patients with Chronic Hepatitis B and Their Influence on HBsAg Levels[J].Journal of Medical Information,2021,34(22):96.[doi:10.3969/j.issn.1006-1959.2021.09.025]
[7]张 瑜,路青华,曹海芳,等.聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响[J].医学信息,2021,34(17):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]
　ZHANG Yu,LU Qing-hua,CAO Hai-fang,et al.Effect of Polyethylene Glycol Interferon,PEG-IFN Combined with Entecavir on Liver Function and Liver Fibrosis in Patients with Chronic Hepatitis B[J].Journal of Medical Information,2021,34(22):114.[doi:10.3969/j.issn.1006-1959.2021.17.029]
[8]姜海燕.恩替卡韦联合复方甘草酸苷治疗乙型肝炎肝硬化对患者肝功能及血清HA、Ⅳ-C、PC-Ⅲ水平的影响[J].医学信息,2022,35(09):144.[doi:10.3969/j.issn.1006-1959.2022.09.036]
　JIANG Hai-yan.Effect of Entecavir Combined with Compound Glycyrrhizin on Liver Function and Serum Levels of HA, Ⅳ-C and PC-Ⅲ in Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2022,35(22):144.[doi:10.3969/j.issn.1006-1959.2022.09.036]
[9]皮青文.恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响[J].医学信息,2022,35(15):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
　PI Qing-wen.Effect of Entecavir Antiviral Therapy on Liver Function and Degree of Liver Cirrhosis in Patients with Chronic Hepatitis B Cirrhosis[J].Journal of Medical Information,2022,35(22):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
[10]谭子跃.干扰素合并恩替卡韦治疗乙型病毒性肝炎患者的疗效及对患者肝功能的影响[J].医学信息,2023,36(20):137.[doi:10.3969/j.issn.1006-1959.2023.20.027]
　TAN Zi-yue.Effect of Interferon Combined with Entecavir in the Treatment of Patients with Hepatitis B and its Effect on Liver Function[J].Journal of Medical Information,2023,36(22):137.[doi:10.3969/j.issn.1006-1959.2023.20.027]

更新日期/Last Update: 2019-11-15